NCT05049447

Pharmacological Effects of Pascoflair® on Brain Activity in Patients Suffering From Test Anxiety

Proof of Effectiveness of Pascoflair Using Qantitative Measurement of Electric Brain Activity During Examination Stress in 40 Subjects Suffering From Test Anxiety. A Double-blind, Randomized, Placebo-controlled, 2-armed, Phase IV Study in Parallel Design.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Pascoe Pharmazeutische Praeparate GmbH · Industry
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

Proof of effectiveness of Pascoflair using qantitative measurement of electric brain activity during examination stress in 40 subjects suffering from test anxiety. A double-blind, randomized, placebo-controlled, 2-armed, Phase IV study in parallel design.

Detailed description

Anxiolytic effects of PASCOFLAIR® shall be tested in subjects suffering from test anxiety after single intake by aid of a newly developed, validated method consisting of a combination of eye tracking (following glances) with neurocode tracking (quantitative EEG with a time resolution of 364 ms).

Conditions

• Stress
• Brain Activity
• Passiflora Incarnata
• Test Anxiety

Interventions

Type	Name	Description
DRUG	Pascoflair	1 x 2 tablets (single-dose)
OTHER	Placebo	1 x 2 tablets (single-dose)

Timeline

• Start date: 2015-05-01
• Primary completion: 2015-08-01
• Completion: 2015-08-01
• First posted: 2021-09-20
• Last updated: 2021-09-20